Led by the brightest minds in the industry
atai is home to some of the most sought-after executives and scientists in the space. Equipped with a diverse and dedicated team, we are making a concerted effort to redefine mental health paradigms.
Guided by a noble mission
We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.
Our unique operating model
Our approach combines funding, access to accelerative platform technologies, as well as scientific and regulatory expertise with a singular focus on developing more rapid-acting and potentially disease-modifying mental health treatments.
Shortcomings of existing therapies
Current standard of care treatments are ineffective for millions worldwide.
Slow onset – Up to 3 months for SSRIs to take full effect
Inadequate response – ~33% of patients with depression become treatment-resistant
Ineffective care– ~60-70% of patients with depression are likely to relapse with current care
High relapse rate – ~75% of patients undergoing OUD therapy experience relapse within 1 year
Addiction – Long-term benzodiazepine use is associated with development of drug dependence
Sexual dysfunction – Side effects of SSRIs include sexual dysfunction
Weight gain – Patients on SSRIs can experience weight gain
Sleep – SSRIs interfere with sleep architecture, potentially complicating the sleep of depressed patients
Our unique approach
Compounds with prior evidence in humans
To minimize development risk, we focus on compounds that have previously been used in humans and have established safety profiles.
Enabling platform technologies
Decentralized drug development
In addition to funding, our evolving companies have access to our deep domain expertise and operational backbone.
WHERE WE’RE HEADED
Our technologies drive efficient drug discovery and improved treatment outcomes.
Our unique model combines funding with operational expertise to develop innovative and impactful CNS therapeutics.OUR MODEL
News & Insights
atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders
atai Life Sciences, a global biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, has acquired a…
Recognify Life Sciences to Commence Phase 2a Study in Cognitive Impairment Associated with Schizophrenia
Recognify Life Sciences, Inc., an atai Life Sciences platform company focused on developing treatments for cognitive impairment with initial efforts…
Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders
Perception Neuroscience, an atai Life Sciences company focused on developing innovative therapies in neuropsychiatric disorders, and Otsuka Pharmaceutical Co., Ltd.,…